Dr. Yi-bin A. Chen, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 134
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Harvard Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 220342 -
Internal Medicine Physician
MA license 220342
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Cooley Dickinson Hospital Inc,the Northampton, MA
- Massachusetts Eye and Ear Infirmary - Boston, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 134
- Services billed
- 895
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 346 | 109 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 331 | 50 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 26 | 24 |
| Hospital discharge day management, more than 30 minutes | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 128 |
| Lorazepam Other prescribers in Boston, MA | 41 |
| Gabapentin Other prescribers in Boston, MA | 22 |
| Prednisone Other prescribers in Boston, MA | 21 |
| Atovaquone | 20 |
| Prevymis (letermovir) | 17 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Boston, MA | 16 |
| Rezurock (belumosudil mesylate) | 14 |
| Famciclovir | 13 |
| Omeprazole Other prescribers in Boston, MA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 32 payments worth $41,508 in total to this clinician.
| Incyte Corporation | $11,380 |
|---|---|
| Csl Behring | $8,966 |
| Syndax Pharmaceuticals, Inc. | $7,165 |
| Alexion Pharmaceuticals, Inc. | $6,500 |
| Daiichi Sankyo Inc. | $4,133 |
| Aimmune Therapeutics, Inc. | $2,975 |
| National Marrow Donor Program | $325 |
| Kite Pharma, Inc. | $33.34 |
| Consulting Fee | $34,281 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $4,550 |
| Travel and Lodging | $1,560 |
| Food and Beverage | $1,118 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Sep 18, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $6,800 |
| Incyte Corporation Jul 3, 2025 | Consulting Fee Niktimvo · Oncology | $6,165 |
| Csl Behring Jan 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,550 |
| Csl Behring May 16, 2025 | Consulting Fee | $4,416 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Alexion Pharmaceuticals, Inc. Oct 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,500 |
| Daiichi Sankyo Inc. Mar 19, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $2,400 |
| Alexion Pharmaceuticals, Inc. Mar 25, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,000 |
| Alexion Pharmaceuticals, Inc. Jul 2, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,000 |
| Daiichi Sankyo Inc. Mar 12, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $1,600 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee Niktimvo · Oncology | $3,425 |
| Incyte Corporation Dec 4, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Orlando, FL | $269 |
| Incyte Corporation Dec 4, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Orlando, FL | $35.95 |
| Alexion Pharmaceuticals, Inc. Oct 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,500 |
| Syndax Pharmaceuticals, Inc. Sep 18, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $6,800 |
| Syndax Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL | $215 |
| Aimmune Therapeutics, Inc. Jul 30, 2025 | Consulting Fee VOWST · GI | $1,400 |
| Incyte Corporation Jul 3, 2025 | Consulting Fee Niktimvo · Oncology | $6,165 |
| Alexion Pharmaceuticals, Inc. Jul 2, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,000 |
| Incyte Corporation Jun 28, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Atlanta, GA | $224 |
| Incyte Corporation Jun 28, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Atlanta, GA | $65.96 |
| Incyte Corporation Jun 27, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Atlanta, GA | $659 |
| Incyte Corporation Jun 27, 2025 | Travel and Lodging Niktimvo · Oncology · travel to Atlanta, GA | $91.07 |
| Aimmune Therapeutics, Inc. Jun 12, 2025 | Consulting Fee VOWST · GI | $1,575 |
| Csl Behring May 16, 2025 | Consulting Fee | $4,416 |
| Alexion Pharmaceuticals, Inc. Mar 25, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,000 |
| Daiichi Sankyo Inc. Mar 19, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $2,400 |
| Daiichi Sankyo Inc. Mar 12, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $1,600 |
| Csl Behring Jan 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,550 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $53,073 in research payments for these studies, mostly to the institutions running them.
- A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
National Marrow Donor Program - Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE)
National Marrow Donor Program - Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03657160
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.